Brief: Tiziana Life Sciences Announces FDA Ind Clearance Of Intranasal Foralumab For The Treatment Of Alzheimer’S Disease
15/08/2023 12:32
Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES FDA IND CLEARANCE OF
INTRANASAL
FORALUMAB FOR THE TREATMENT OF ALZHEIMER’S DISEASE
* TIZIANA LIFE SCIENCES: FORALUMAB TO ADVANCE INTO PHASE 2
HUMAN
CLINICAL TRIALS USING WORLD'S ONLY FULLY HUMAN INTRANASAL
ANTI-CD3 MONOCLONAL ANTIBODY
* TIZIANA LIFE SCIENCES LTD: TRIAL TO BE OVERSEEN BY BRIGHAM
AND
WOMEN'S HOSPITAL, A FOUNDING MEMBER OF MASS GENERAL BRIGHAM
HEALTHCARE SYSTEM
Source text for Eikon: ID:nGNX9YVpWq
Further company coverage: TLSA.O
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis